Scand Cardiovasc J. 2026 Jul 3:1-3. doi: 10.1080/14017431.2026.2699501. Online ahead of print.
ABSTRACT
OBJECTIVES: To critically assess the ESCAPER study (Ekström et al., 2025, Scandinavian Cardiovascular Journal), which investigates cardiovascular resilience in high-risk individuals with type 1 diabetes (T1D), obesity, or kidney failure, focusing on internal inconsistencies, methodological challenges, and alignment with existing literature.
DESIGN: This Letter to the Editor analyzes the ESCAPER study's rationale, protocol, and preliminary findings. We evaluate inclusion criteria, genetic analysis, and methodological rigor, comparing them to studies like FinnDiane. Concerns include T1D patients with microvascular complications as "escapers," non-T1D-specific polygenic scores, small sample sizes, selection bias from voluntary recruitment, and inconsistent imaging protocols. We pose questions to clarify these issues.
RESULTS: Including T1D patients with microalbuminuria or simplex retinopathy as "escapers" conflicts with the study's aim, as these conditions suggest vascular pathology. Reliance on coronary artery disease and diabetes mellitus polygenic scores overlooks T1D-specific genetic factors, diverging from FinnDiane findings. Methodological flaws, including no predefined primary outcome, small sample sizes (e.g., n = 4 in kidney failure group), voluntary recruitment bias, and variable imaging protocols, limit generalizability and data consistency.
CONCLUSIONS: The ESCAPER study's focus on cardiovascular resilience is novel but hampered by inconsistencies, literature discrepancies, and methodological limitations. Clarifying inclusion criteria, genetic markers, statistical power, bias mitigation, and data standardization is essential. We urge the authors to address these concerns to enhance the study's contribution to precision medicine.
PMID:42396621 | DOI:10.1080/14017431.2026.2699501